Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Pucotenlimab combined with MRG002

Phase 2Small molecule

ZZhiguo Luo, MD, PhD

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cancer of Unknown PrimaryNot yet recruiting

Cancer of Unknown PrimaryPhase 2

Not yet recruiting

Timeline

Expected Milestones

Q3 2028

Phase 2Not yet recruiting

Cancer of Unknown Primary

NCT06869174

Clinical

Trials by Indication[1]

Cancer of Unknown Primary1 trial

Pucotenlimab Combined with MRG002 for HER2-positive Cancer of Unknown Primary

Not yet recruiting·ZZhiguo Luo, MD, PhD·Phase 2·NCT06869174·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Pucotenlimab combined with MRG002. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pucotenlimab combined with MRG002 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pucotenlimab combined with MRG002. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Zhiguo Luo, MD, PhD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: ZZhiguo Luo, MD, PhD

Related News